FindTrial
Sign In

Sequential neoadjuvant ifosfamide and doxorubicin in localized high-grade soft tissue sarcoma of extremities and trunk wall

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-510185-27-00
Enrollment
50
Registered
2024-11-07
Start date
2021-03-01
Completion date
Unknown
Last updated
2025-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with high-grade soft tissue sarcoma of the extremities and trunk wall

Brief summary

Overall response rate (ORR), defined as partial or complete response as assessed by RECIST 1.1.

Detailed description

Diseasefree survival and overall survival, Overall response rate defined as partial or complete response, Adverse event, serious adverse event and dose reductions or discontinuation due to toxicity., Change from baseline in EORTC QLQ-C30 scores.

Interventions

DRUGAdriamycin 2 mg/ml injeksjonsvæske
DRUGoppløsning
DRUGHoloxan 1000 mg pulver til injeksjonsvæske/infusjonsvæske

Sponsors

Oslo University Hospital HF
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Overall response rate (ORR), defined as partial or complete response as assessed by RECIST 1.1.—

Secondary

MeasureTime frame
Diseasefree survival and overall survival, Overall response rate defined as partial or complete response, Adverse event, serious adverse event and dose reductions or discontinuation due to toxicity., Change from baseline in EORTC QLQ-C30 scores.—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026